Compare Gartner Inc (IT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Recursion Pharmaceuticals Inc — how do they compare? Gartner Inc trades at $195.41 (market cap $12.34B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Gartner Inc is far larger — about 5.8× Recursion Pharmaceuticals Inc's market cap, and Gartner Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| IT | RXRX | |
|---|---|---|
Market Cap | $12.34B | $2.14B |
Volume | 919,809 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $258.17 | $6.79 |
52-Week Low | $125.68 | $2.84 |
Typical Hold Time | 64 Days | 22 Days |
Enterprise Value | $14.08B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $185.77, up 0.46% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 69.63% gross margin and 12% net income margin, though 2025 net income declined to $729 million. Recent news highlights AI advisory demand and a shareholder investigation, while analyst consensus is mixed with a $174.63 price target below the current price.
Outlook remains supported by high ROE and consulting industry growth, but risks include the shareholder fiduciary probe and volatile cash flows. The stock faces resistance near $188, with valuation metrics like P/E of 17.57 appearing reasonable if earnings stabilize.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
